OBJECTIVE: MRI provides clear visualization of spinal cord, tumor, and bone for patient positioning and verification during MRI-guided radiotherapy (MRI-RT). Therefore, we wished to evaluate spine stereotactic ablative radiotherapy (SABR) feasibility with MRI-RT. Given dosimetric limitations of first generation Co-60 MRI-RT, we then evaluated improvements by newer linear accelerator (linac) MRI-RT. METHODS: Nine spinal metastases were treated with Co-60 MRI-RT. Seven received a single 16 Gy fraction, and two received three fractions totaling 24 or 30 Gy. After replanning with linac MRI-RT software, comparisons of organ at risk and dose spillage objectives between Co-60 and linac plans were performed. RESULTS: Spinal cord and cauda equina dose constraints were met in all Co-60 cases. Treatments were delivered successfully with real-time imaging during treatment and no treatment-related toxicities. While limits for dose spillage into surrounding soft tissues were not achieved due to the limitations of the Co-60 system, this could be corrected with linac MRI-RT delivery. CONCLUSIONS: MRI-RT SABR of spinal metastases is feasible with Co-60 MRI-RT. Dose delivery is improved by linac MRI-RT. ADVANCES IN KNOWLEDGE: This is the first report of MRI-RT for SABR of spinal metastases. The enhanced visualization of anatomy by MRI may facilitate RT dose escalation for spine SABR.
OBJECTIVE: MRI provides clear visualization of spinal cord, tumor, and bone for patient positioning and verification during MRI-guided radiotherapy (MRI-RT). Therefore, we wished to evaluate spine stereotactic ablative radiotherapy (SABR) feasibility with MRI-RT. Given dosimetric limitations of first generation Co-60 MRI-RT, we then evaluated improvements by newer linear accelerator (linac) MRI-RT. METHODS: Nine spinal metastases were treated with Co-60 MRI-RT. Seven received a single 16 Gy fraction, and two received three fractions totaling 24 or 30 Gy. After replanning with linac MRI-RT software, comparisons of organ at risk and dose spillage objectives between Co-60 and linac plans were performed. RESULTS: Spinal cord and cauda equina dose constraints were met in all Co-60 cases. Treatments were delivered successfully with real-time imaging during treatment and no treatment-related toxicities. While limits for dose spillage into surrounding soft tissues were not achieved due to the limitations of the Co-60 system, this could be corrected with linac MRI-RT delivery. CONCLUSIONS: MRI-RT SABR of spinal metastases is feasible with Co-60 MRI-RT. Dose delivery is improved by linac MRI-RT. ADVANCES IN KNOWLEDGE: This is the first report of MRI-RT for SABR of spinal metastases. The enhanced visualization of anatomy by MRI may facilitate RT dose escalation for spine SABR.
Authors: Govind B Chavhan; Paul S Babyn; Bhavin G Jankharia; Hai-Ling M Cheng; Manohar M Shroff Journal: Radiographics Date: 2008 Jul-Aug Impact factor: 5.333
Authors: Jean-Pierre Bissonnette; Doug Moseley; Elizabeth White; Michael Sharpe; Tom Purdie; David A Jaffray Journal: Int J Radiat Oncol Biol Phys Date: 2008 Impact factor: 7.038
Authors: Amol J Ghia; Nandita Guha-Thakurta; Kenneth Hess; James N Yang; Stephen H Settle; Hadley J Sharpe; Jing Li; MaryFrances McAleer; Eric L Chang; Claudio E Tatsui; Paul D Brown; Laurence D Rhines Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-09 Impact factor: 7.038
Authors: Chang Heon Choi; So-Yeon Park; Jung-In Kim; Jin Ho Kim; Kyubo Kim; Joel Carlson; Jong Min Park Journal: Br J Radiol Date: 2016-12-08 Impact factor: 3.039
Authors: Peter C Gerszten; Steven A Burton; Cihat Ozhasoglu; William J Vogel; William C Welch; Joseph Baar; David M Friedland Journal: J Neurosurg Spine Date: 2005-10
Authors: Camille E Noel; Parag J Parikh; Christopher R Spencer; Olga L Green; Yanle Hu; Sasa Mutic; Jeffrey R Olsen Journal: Acta Oncol Date: 2015-07-24 Impact factor: 4.089
Authors: Peter C Gerszten; Steven A Burton; Annette E Quinn; Sanjiv S Agarwala; John M Kirkwood Journal: Stereotact Funct Neurosurg Date: 2006-03-08 Impact factor: 1.875
Authors: Samuel Ryu; Ryan Jin; Jian-Yue Jin; Qing Chen; Jack Rock; Joseph Anderson; Benjamin Movsas Journal: J Pain Symptom Manage Date: 2008-01-22 Impact factor: 3.612
Authors: Danilo Maziero; Michael W Straza; John C Ford; Joseph A Bovi; Tejan Diwanji; Radka Stoyanova; Eric S Paulson; Eric A Mellon Journal: Front Oncol Date: 2021-03-08 Impact factor: 6.244